RFI - GEIS Network Illumina Sequencing Platform Modernization

The Request for Information (RFI) from the Defense Health Agency (DHA) seeks to identify commercial solutions for modernizing the Global Emerging Infections Surveillance (GEIS) Network's Illumina Sequencing Platform. The RFI aims to replace existing MiSeq (RUO), MiniSeq, and iSeq100 sequencers with Illumina MiSeq i100 Plus Next-Generation Sequencing systems. The upgrade is critical for maintaining global public health surveillance and leveraging the MiSeq i100 Plus's proprietary XLEAP-SBS chemistry, which offers room-temperature stable reagents and integrated DRAGEN Bio-IT Platform for onboard data analysis. This onboard analysis capability is essential for operating within a contained, air-gapped security environment, simplifying the Risk Management Framework process and obtaining Authority to Operate within the Department of War (DoW). The RFI emphasizes Illumina's sole manufacturing of the MiSeq i100 and associated reagents due to proprietary technology and unique system architecture. Responses, including technical data and adherence to specific formatting, are due by May 29, 2026, 8:00 A.M. EST, and should address requirements for delivery, installation, training, annual service, and room-temperature stable reagents across 18 CONUS and OCONUS laboratory sites.